Pa February 9, 2026, tsamba lovomerezeka la Center for Drug Evaluation (CDE) la National Medical Products Administration (NMPA) linalengeza kuti ZL-1310 yobayira jakisoni, yomwe ndi DLL3-target antibody-drug conjugate (ADC), ikukonzekera kupatsidwa dzina la Breakthrough Therapy.
Monga membala wa Peking University Cancer Hospital Medical Consortium komanso chipatala chachiwiri chamakono cha khansa ku Beijing, Dipatimenti Yapadziko Lonse ya Beijing South Region Oncology Hospital imagwiritsa ntchito njira yolimba yodziwira matenda ndi chithandizo cha matenda osiyanasiyana kuti iphatikize mwachangu njira zochizira matenda otsogola padziko lonse lapansi mu mapulani ochizira odwala apadziko lonse lapansi. Ngati inu kapena wokondedwa wanu mukukumana ndi mavuto a chithandizo chachiwiri kapena chamtsogolo cha khansa ya m'mapapo yaing'ono, chonde werengani mosamala zomwe zili pansipa ndikulankhulana nafe nthawi yomweyo.
Lumikizanani ndi Dipatimenti Yapadziko Lonse ya Chipatala cha Oncology ku Beijing South Region tsopano:
- Foni: 400-880-3716
- WeChat ID: 17801183037
- Email ①: 100085_010@163.com
- Email ②: myimmnet@163.com
**Zovuta Kwambiri: Kugwira Ntchito Mpaka 86% mwa Odwala Omwe Ali ndi Matenda a Ubongo**
Pa Msonkhano Wapachaka wa American Society of Clinical Oncology (ASCO) wa 2025, deta yapadziko lonse ya kafukufuku wa zachipatala wa gawo 1a/1b wa ZL-1310 inaperekedwa.
Kwa odwala omwe adachiritsidwa kale (chithandizo chachiwiri):
- Chiŵerengero chosatsimikizika cha mayankho olondola (uORR) chafika pa 67%, ndi chiŵerengero chowongolera matenda (DCR) cha 97%.
- Mu gulu la mlingo woyenera kwambiri wachilengedwe (1.6 mg/kg): Chiŵerengero cha mayankho ofunikira (ORR) chinakwera kufika pa 79%, ndi chiŵerengero cha kulamulira matenda (DCR) cha 100%.
- Izi zikutanthauza kuti: Pafupifupi odwala onse 10 omwe adalandira mlingo uwu adakwanitsa kuchepetsa chotupa, ndipo odwala pafupifupi 8 adachepetsa kwambiri chotupa.
Kwa odwala omwe ali ndi vuto lalikulu la metastasis ya ubongo:
- Odwala omwe ali ndi matenda a ubongo omwe amayamba chifukwa cha metastases: Chiŵerengero cha mayankho ofunikira (ORR) chinali 68%.
- Odwala omwe sanalandirepo chithandizo cha radiotherapy ya cranial: Objective response rate (ORR) inali yokwera kufika pa 86%!
Deta iyi ndi yodabwitsa. Mankhwala achikhalidwe a chemotherapy amavutika kulowa mu chotchinga cha magazi ndi ubongo, koma ZL-1310 ikuwonetsa mphamvu yolimbana ndi chotupa mkati mwa mutu. Kwa odwala ochokera kumayiko ena omwe akuda nkhawa ndi zotsatirapo za chithandizo cha radiotherapy cha ubongo wonse, izi zikuyimira chiyembekezo chachikulu "chopewa kuwala kwa ubongo."
**Mbiri ya Chitetezo:** Mu gulu la <2.0 mg/kg la mlingo, kuchuluka kwa zochitika zoyipa zokhudzana ndi chithandizo (TRAEs) za giredi 3 kapena kupitirira apo kunali 6% yokha, popanda zochitika zokhudzana ndi chithandizo zokhudzana ndi matenda a m'mapapo (ILD) kapena zochitika zosiya chithandizo zomwe zanenedwa.
—
**III. N’chifukwa Chiyani Muyenera Kusankha Dipatimenti Yapadziko Lonse ya Chipatala cha Oncology ku Beijing South Region?**
Kwa odwala ochokera kumayiko ena, kupeza njira zatsopano zochiritsira sikuti kungokhudza "ngati mankhwalawo alipo," komanso njira yokhazikika yokhudza "amene angawagwiritse ntchito, momwe angawagwiritsire ntchito, komanso amene angayang'anire zotsatirapo zake."
Dipatimenti ya Chipatala cha Oncology ku Beijing South Region International imapereka mayeso oyembekezera komanso kasamalidwe ka nthawi zonse ka mankhwala apamwamba monga ZL-1310 kwa odwala oyenerera. Kaya ndinu ochokera ku Southeast Asia, Middle East, Europe, kapena America, tili ndi njira yodziwika bwino yoperekera chithandizo chamankhwala padziko lonse lapansi.
Timapereka chithandizo chokwanira kuyambira pa upangiri wa dokotala asanapite kuchipatala, kumasulira zilankhulo zosiyanasiyana, makalata a visa yachipatala, mpaka kutsatira malangizo ochiritsira. Kutsatira kwambiri mfundo yakuti “dokotala mmodzi, wodwala mmodzi, chipinda chimodzi” kumatsimikizira kuti chinsinsi chanu ndi ulemu wanu zimalemekezedwa mokwanira, ngakhale kudziko lina.
Pakadali pano, ZL-1310 yapatsidwa udindo wa Orphan Drug ndi Fast Track Designation ndi US FDA. Kuphatikizidwa kwake komwe kukukonzekera mu ulamuliro wa Breakthrough Therapy ku China kudzathandizira kwambiri kupezeka kwake ku China.
Musalole kuti zopinga za chilankhulo, mipata yopezera chidziwitso, kapena njira zovuta zikulepheretseni kupeza chithandizo chapamwamba. Dipatimenti ya Beijing South Region Oncology Hospital International yakhazikitsa njira yobiriwira kwa odwala ochokera kumayiko ena.
Imbani foni kapena titumizireni uthenga kudzera pa WeChat kapena imelo kuti mugawane za vuto lanu. Alangizi athu azachipatala adzapereka mayeso oyamba mkati mwa maola 24.
- Foni (upangiri wa maola 24): 400-880-3716
- WeChat (kulankhulana nthawi yomweyo): 17801183037 (imathandizira Chingerezi ndi Chitchaina)
- Imelo (yopezera zolemba zachipatala):
- 100085_010@163.com
- myimmnet@163.com
Nthawi yotumizira: Feb-12-2026